Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1361-1370 of 3418 for cancer

Edit search filters
  1. Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

    Rochester, MN

  2. Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia

    Scottsdale/Phoenix, AZ

  3. Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma

    Rochester, MN

  4. A Patient Access Program of Olaratumab for the Continued Treatment of Soft Tissue Sarcoma

    Jacksonville, FL

  5. Reduced Dose Hypofractionated Radiotherapy For Indolent Non-hodgkin Lymphoma

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ, Albert Lea, MN, Eau Claire, WI, La Crosse, WI, Mankato, MN

  6. Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant

    Scottsdale/Phoenix, AZ

  7. A Study to Evaluate Brigatinib Before Brain Irradiation

    Rochester, MN

  8. Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

    Rochester, MN

  9. Phase III Copanlisib in Rituximab-refractory iNHL

    Rochester, MN

  10. A Study of a Mindfulness-Based Intervention with a Wearable Wellness Brain Sensing Device in Newly Diagnosed Breast Cancer Patients Undergoing Surgery

    Rochester, MN

.

Mayo Clinic Footer